Опубликована: Янв. 1, 2024
Язык: Английский
Frontiers in Cardiovascular Medicine, Год журнала: 2025, Номер 11
Опубликована: Янв. 15, 2025
Myocardial fibrosis (MF) is a common pathological manifestation of many cardiovascular diseases, such as myocardial infarction, ischemia, and sudden cardiac death. It characterized by excessive proliferation activation fibroblasts, transformation into myofibroblasts, and, eventually, deposition the extracellular matrix, resulting in heart damage. Currently, modern drugs angiotensin-converting enzyme inhibitors, diuretics, β-blockers can improve clinical treatment, but their therapeutic effect on this disease limited, with obvious side effects high cost. Traditional Chinese medicine (TCM) has advantages multiple targets, low cost, few effects. medicines, Salvia miltiorrhiza, Astragalus, Angelica extracts, patent Qiliqiangxin capsules, Shenqi Yiqi dropping pills, Tongxinluo fibrosis. In review, current Western methods for treating are discussed. The signaling pathways targets involved treatment This review aimed to provide valuable insights ideas both basic research
Язык: Английский
Процитировано
0
Pharmaceuticals, Год журнала: 2025, Номер 18(3), С. 413 - 413
Опубликована: Март 14, 2025
Astragali Radix (AR), a traditional Chinese herbal medicine, is derived from the dried roots of Astragalus membranaceus (Fisch.) Bge. var. mongholicus (Bge.) Hsiao (A. mongholicus, AMM) or Bge membranaceus, AM). According to medicine (TCM) theory, AR believed tonify qi, elevate yang, consolidate body’s surface reduce sweating, promote diuresis and swelling, generate body fluids, nourish blood. It has been widely used treat general weakness chronic illnesses improve overall vitality. Extensive research identified various medicinal properties AR, including anti-tumor, antioxidant, cardiovascular-protective, immunomodulatory, anti-inflammatory, anti-diabetic, neuroprotective effects. With advancements in technology, methods such as computer-aided drug design (CADD) artificial intelligence (AI) are increasingly being applied development TCM. This review summarizes progress on over past decades, providing comprehensive overview its efficacy, botanical characteristics, distribution, chemical constituents, phytochemistry. aims enhance researchers’ understanding pharmaceutical potential, thereby facilitating further utilization.
Язык: Английский
Процитировано
0
Frontiers in Pharmacology, Год журнала: 2025, Номер 16
Опубликована: Апрель 10, 2025
Arrhythmia, a common cardiovascular disorder, results from disturbances in cardiac impulse generation and conduction, leading to decreased output myocardial oxygenation, with potentially life-threatening consequences. Despite advancements therapeutic approaches, the incidence mortality associated arrhythmia remain high, drug-related adverse effects continue pose significant challenges. Traditional Chinese Medicine (TCM) has attracted considerable attention for its potential as complementary alternative approach treating diseases, including arrhythmia. Astragalus, prominent herb TCM, is commonly used clinical practice multi-faceted properties, encompassing anti-arrhythmic, cardiotonic, anti-inflammatory, immunomodulatory effects. Astragaloside IV, primary active compound Astragalus membranaceus , demonstrated cardioprotective through mechanisms such antioxidant, anti-apoptotic activities. Although evidence suggests that astragaloside IV holds promise treatment, comprehensive reviews of specific applications are scarce. This review systematically explores pharmacological properties underlying treatment. Utilizing targeted search databases PubMed, Web Science, Cochrane Library, Embase, CNKI, Wanfang Data, we summarize recent findings examine IV’s prevention Our analysis aims provide theoretical foundation development novel treatment strategies, while offering insights into future research directions application.
Язык: Английский
Процитировано
0
Journal of Ethnopharmacology, Год журнала: 2024, Номер 337, С. 118827 - 118827
Опубликована: Сен. 16, 2024
Язык: Английский
Процитировано
2
Frontiers in Cardiovascular Medicine, Год журнала: 2024, Номер 11
Опубликована: Авг. 6, 2024
Objectives The aim of this meta-analysis is to evaluate the effect astragalus injection (AI) on left ventricular remodeling (LVR) in patients with heart failure mildly reduced ejection fraction (HFmrEF). Methods randomized controlled trials (RCTs) AI treating HFmrEF were retrieved from 8 major English and Chinese electronic databases, up until November 30, 2023. To methodological quality included studies, Cochrane bias risk tool Modified Jadad Scale employed. Stata 17.0 software was utilized for statistical analysis, sensitivity assessment publication bias. Results Ten RCTs 995 (562 males 433 females) identified. Meta-analysis indicated that compared conventional treatment (CT), significantly improved LVR, specifically increasing (LVEF, MD = 4.56, 95% CI: 3.68–5.44, p < 0.00001), decreasing end-diastolic volume (LVEDV, −7.89, −11.13 −4.64, diameter (LVEDD, −4.18, −5.79 −2.56, end-systolic (LVESV, −8.11, −11.79 −4.43, (LVESD, −3.42, −4.90 −1.93, 0.00001). also clinical efficacy (RR 4.62, 3.11–6.88, N-terminal pro-brain natriuretic peptide (NT-pro BNP, −27.94, −43.3 −12.36) level, without incidence adverse reactions 1.60, 0.59–4.29, 0.35). Sensitivity analysis confirmed reliability merged results, Begg's Egger's tests showed no significant Conclusion systematic review revealed combining CT improves LVR events patients. However, caution needed interpreting results due limited evidence. Future high-quality are support these conclusions. Systematic Review Registration https://www.crd.york.ac.uk/prospero/ , PROSPERO [CRD42022347248].
Язык: Английский
Процитировано
1
Опубликована: Янв. 1, 2024
Язык: Английский
Процитировано
0